WCN25-2620 CUMULATIVE EFFECTS OF THE ALDOSTERONE SYNTHASE INHIBITOR VICADROSTAT COMBINED WITH EMPAGLIFLOZIN ON ALBUMINURIA IN PEOPLE WITH CKD

• Peter Rossing,
• Sibylle Hauske,
• Lisa Cronin,
• Hiddo Heerspink,
• Juliane Meyerhoff,
• Shimoli Shah,
• Zhichao Sun,
• Dick de Zeeuw,
• Katherine Tuttle

Affiliations

Peter Rossing

Endocrinology, Steno Diabetes Center Copenhagen/Københavns Univ, Herlev, Denmark

Sibylle Hauske

CRM Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany

Lisa Cronin

CRM Medicine, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States

Hiddo Heerspink

Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, Netherlands

Juliane Meyerhoff

CRM Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany

Shimoli Shah

Medical Safety, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States

Zhichao Sun

Bio Statistics and Data Science, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, United States

Dick de Zeeuw

University Medical Center, University of Groningen, Groningen, Netherlands

Katherine Tuttle

Division of Nephrology and Kidney Research Institute, Providence Medical Research Center, Spokane, WA, United States